| Topic |
Issue # |
|
Aaron Diamond Research Center |
384 |
| Abbreviated Guide ... HIV |
380 |
| Access to care |
387 |
| Achmat, Zackie |
387 |
| ACT UP |
385 |
| ACTG 384 trial changes |
382 |
| Activism |
377, 379, 385, 387
|
|
ADAP crisis |
380, 381, 382, 386, 387
|
| ADAP waiting list advice |
381 |
| Advocacy |
387 |
| African Services Committee |
385 |
| AIDS Drug Assistance Program |
(see ADAP) |
| AIDSWatch lobbying |
380 |
| Amprenavir approved |
378 |
| Anti-HIV factor |
384 |
| Atazanavir |
379 |
| Avascular necrosis |
379 |
|
Barcelona conference take-home messages |
382 |
| Barcelona conference visa problems |
381 |
| Barcelona conference Web sites |
381 |
| Barcelona online reports |
382 |
| Benefits issues |
377 |
| Bone problems |
379 |
| Buyers' club list |
387 |
|
Chinese activist, Dr. Wan Yanhai |
383 |
| Coca-Cola protest |
384 |
| Conferences and meetings list |
378 |
| Congress |
387 |
| Cost of international conferences |
381 |
| Counterfeit drugs |
380 |
| C-Reactive Protein |
385 |
|
d4T -- side effects |
378 |
| d4T and lipoatrophy |
378 |
| Deca Durabolin availability problems |
381 |
| Defensins |
384 |
| Doctors Without Borders |
385 |
| Doha, Qatar |
386 |
| Drug interactions |
377 |
| Drug pricing |
377 |
|
Efavirenz once daily |
378 |
| Epogen |
380 |
|
Facial injections |
378 |
| Fundraising |
377 |
| Fuzeon |
(see T-20) |
|
Global Fund |
379 |
| Government AIDS Web site |
386 |
| Grossman, Dr. Howard, interview |
383 |
| Guidelines on metabolic complications |
385 |
|
Health GAP |
385 |
| Heart disease prevention |
377 |
| Heart disease |
385 |
| Hepatitis C |
384 |
| HIV harm reduction |
384 |
|
ICAAC conference, clinical trials |
384 |
| Integrase inhibitor |
379 |
| Intellectual property |
385, 386
|
| Interactions of drugs |
377 |
|
Johns Hopkins short guide |
380 |
| Junk foods |
377 |
|
Kaiser, Jon, M.D. |
383 |
|
Lactic acidosis |
378 |
| Legal issues |
377 |
| Lipoatrophy -- drug changes |
378 |
| Lipodystrophy strategies |
383 |
|
Marijuana lung report |
385 |
| Marijuana |
379 |
| Measles may suppress HIV |
379 |
| Medicaid crisis |
387 |
| Medicaid funding |
380 |
| Medical privacy rules |
379 |
| Medical research funding |
377 |
| Metabolic complications -- guidelines |
385 |
| MSF (Doctors Without Borders) |
385 |
|
Nandrolone availability problems |
381 |
| Nandrolone generic |
382 |
| NATAF conference |
382 |
| NDRI (National Disease Research Interchange) |
385 |
| Network of People ... Nigeria |
385 |
| Neuromuscular weakness |
378 |
| Nevirapine patient assistance program |
385 |
| New drugs at Retroviruses conference |
379 |
| Nigeria -- patent meeting |
385 |
| Nonoxynol-9 dangers |
381 |
| Nonoxynol-9 dangers |
384 |
|
Once-a-day dosing |
383 |
| Oxfam |
385 |
|
Patents on pharmaceuticals |
385, 386
|
| Patient assistance programs |
385 |
| Peginterferon (hepatitis C) |
384 |
| PHATAM (Pan African HIV/AIDS Treatment Access Movement) |
383 |
| Philadelphia, AIDS Education Month |
380 |
| Political organizing |
387 |
| Prevention -- tenofovir |
385 |
| Pricing of drugs |
377 |
| Protease inhibitors |
383 |
|
Remune controversy |
380 |
| Resistance testing |
383 |
| Retroviruses conference |
378, 387
|
| Retroviruses conference, Web coverage |
378 |
| Ribavirin (hepatitis C) |
384 |
|
S-1360 integrase inhibitor |
379 |
| Search for a Cure |
387 |
| Serostim |
380 |
| Smallpox vaccination begins |
386 |
| Smallpox vaccination questions |
387 |
| Superinfection risk |
383 |
|
T-20 |
383, 384
|
|
| Tenofovir access in poor countries |
386 |
| Tenofovir for prevention |
385 |
| Tenofovir |
377, 383
|
| Tipranavir |
379 |
| Tissue donation |
385 |
| TMC125 |
379 |
| Topoisomerase inhibitors |
379 |
| Treatment Action Movement of Nigeria |
385 |
| Treatments, misc. experimental |
377 |
|
U.S. government AIDS Web site |
386 |
|
Vaccine Research Center, NIAID |
385 |
| Vaccine trial |
385 |
| Viread |
377 |
| Visa problems |
381 |
|
Wan Yanhai released |
384 |
| Wan Yanhai |
383 |
| WTO trade rules |
386 |
This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
Email
Print-Friendly
Glossary
